Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Cambrex Reports Second Quarter 2010 Results


      News provided by

      Cambrex Corporation

      Aug 03, 2010, 04:12 ET

      Share this article

      Share this article


      EAST RUTHERFORD, N.J., Aug. 3 /PRNewswire-FirstCall/ -- Cambrex Corporation (NYSE: CBM) reports second quarter results for the period ended June 30, 2010.

      Highlights

      • Reported sales decreased by 4.0%, and excluding the impact of foreign currency, sales decreased 1.8% compared to second quarter 2009.  
      • EBITDA from continuing operations was $12.1 million in the second quarter 2010 compared to $13.7 million in the same quarter last year.  
      • Income from continuing operations was $3.7 million in the second quarter 2010 compared to $5.5 million for the second quarter 2009.  
      • Debt, net of cash was $77.0 million at the end of second quarter 2010, a decrease of $8.2 million during the quarter excluding a negative $2.5 million impact of currency on foreign cash balances.

      Second Quarter 2010 Operating Results – Continuing Operations

      Second quarter 2010 sales of $57.4 million were 4.0% lower than the second quarter 2009.  Excluding a 2.2% unfavorable impact of foreign exchange, reflecting a stronger U.S. dollar, sales decreased 1.8%.  The decrease is primarily due to lower demand for certain larger products including the effects of a supply chain disruption at a customer's facility, lower pricing on generic active pharmaceutical ingredients ("APIs") and a renegotiated contract extension for certain drug delivery products resulting in lower pricing.  These decreases were partially offset by higher sales volume of controlled substances and generic APIs.

      Second quarter 2010 Gross Margin decreased to 31.2% of sales from 32.9% during the second quarter 2009, with foreign currency favorably impacting gross margin by 0.9% in the second quarter 2010.  Lower pricing, unfavorable product mix and inefficiencies related to the ramp-up of the new addition to the Company's manufacturing facility in Italy were the main drivers of the lower margins.

      Selling, General and Administrative Expenses in the second quarter 2010 were $8.2 million compared to $8.5 million in the same period last year.  The decrease is a result of lower legal fees and insurance premiums.

      Research and Development Expenses increased to $2.8 million in the second quarter 2010 from $2.2 million in the second quarter 2009 primarily due to higher process development costs related to the IEP acquisition, and the development of other new products and technology platforms.

      As a result of the above items, Operating Profit decreased to $6.9 million in the second quarter 2010 from $9.0 million in the second quarter 2009.  

      The Provision for Income Taxes totaled $2.1 million, a 35.9% effective tax rate, in the second quarter 2010.  The Company's effective tax rate has been and is expected to remain highly sensitive to the geographic mix of income due to the Company's inability to recognize tax benefits where there has been a recent history of losses, primarily in the U.S.

      Income from Continuing Operations for the second quarter 2010 was $3.7 million or $0.12 per share compared to $5.5 million or $0.19 per share in the second quarter 2009.  

      Capital expenditures and depreciation for the second quarter 2010 were $2.4 million and $5.2 million compared to $3.6 million and $4.7 million in the second quarter 2009, respectively.

      Steven M. Klosk, President and Chief Executive Officer, said, "I am encouraged by several recent trends and developments within our business.  Orders for generic APIs continued to be strong through the first six months compared to last year, the number of requests for proposals for clinical stage products has been trending up, there has been increased demand for our controlled substances products and cash flow for the quarter was very positive.

      "We continue to be very excited about our recently acquired biocatalysis business, Cambrex IEP, which closed its first long-term licensing contract with a large pharmaceutical company since we acquired it last quarter.  IEP's capabilities and technologies have been favorably received by the customers that our team has met with in the last three months, and our assessment of the opportunities to commercialize our technology is ongoing and very positive.

      "We are making progress in securing new supply agreements for our drug delivery products and introducing new generic products, which combined with an ongoing focus on cost reductions throughout the business, should mitigate price declines in those categories."

      Discontinued Operations

      Discontinued Operations in the second quarter 2010 financial statements includes a benefit as a result of the expiration of a contingent liability and charges for environmental remediation related to sites of divested businesses.  

      Guidance – Continuing Operations

      The Company continues to expect that sales for 2010, excluding the impact of foreign currency, will be between a decline of 5% and an increase of 1% versus 2009, and that full year 2010 EBITDA will be between $41 and $47 million.

      For 2010, capital expenditures are expected to be approximately $12 to $15 million and depreciation is expected to be $21 to $23 million.

      The financial information contained in this press release is unaudited, subject to revision and should not be considered final until the second quarter 2010 Form 10-Q is filed with the SEC.

      Conference Call and Webcast

      The Conference Call to discuss second quarter 2010 results will begin at 8:30 a.m. Eastern Time on Wednesday, August 4, 2010 and last approximately 45 minutes.  Those wishing to participate should call 1-888-631-5931 for domestic and +1-913-981-5544 for international.  Please use the pass code 7920949 and call approximately 10 minutes prior to start time.  A webcast is available from the Investors section on the Cambrex website located at www.cambrex.com and can be accessed for 30 days following the conference call.  A telephone replay of the conference call will be available through Wednesday, August 11, 2010 by calling 1-888-203-1112 for domestic and +1-719-457-0820 for international.  Please use the pass code 7920949 to access the replay.  

      Forward Looking Statements

      This document may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and Rule 3b-6 under The Securities Exchange Act of 1934, as amended, including, without limitation, statements regarding expected performance, especially expectations with respect to sales, research and development expenditures, earnings per share, capital expenditures, acquisitions, divestitures, collaborations, or other expansion opportunities.  These statements may be identified by the fact that they use words such as "expects," "anticipates," "intends," "estimates," "believes" or similar expressions in connection with any discussion of future financial and operating performance.  Any forward-looking statements are qualified in their entirety by reference to the factors discussed throughout the Company's public filings.  Any forward-looking statements contained herein are based on current plans and expectations and involve risks and uncertainties that could cause actual outcomes and results to differ materially from current expectations including, but not limited to, global economic trends, pharmaceutical outsourcing trends, competitive pricing or product developments, government legislation and regulations (particularly environmental issues), tax rate, interest rate, technology, manufacturing and legal issues, including the outcome of outstanding litigation disclosed in the Company's public filings, the Company's ability to satisfy the continued listing standards of the New York Stock Exchange, changes in foreign exchange rates, uncollectible receivables, loss on disposition of assets, cancellation or delays in renewal of contracts, lack of suitable raw materials or packaging materials, the Company's ability to receive regulatory approvals for its facilities or products and other factors described under the caption "Risk Factors That May Affect Future Results" in the Company's Annual Report on Form 10-K for the year ended December 31, 2009.  Any forward-looking statement speaks only as of the date on which it is made, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.  New factors emerge from time to time and it is not possible for the Company to predict which will arise.  In addition, the Company cannot assess the impact of each factor on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

      For further details and a discussion of these and other risks and uncertainties, investors are cautioned to review the Cambrex 2009 Annual Report on Form 10-K, including the Forward-Looking Statement section therein, and other filings with the U.S. Securities and Exchange Commission.  

      About Cambrex

      Cambrex provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics including APIs, advanced intermediates, enhanced drug delivery, and other products for branded and generic pharmaceuticals.  The Company currently employs approximately 850 people worldwide.  For more information, please visit www.cambrex.com.

      CAMBREX CORPORATION

      Statements of Profit and Loss

      For the Quarters Ended June 30, 2010 and 2009

      (in thousands)













      2010


      2009





      % of





      % of



      Amount


      Sales



      Amount


      Sales











      Gross Sales

      $

      57,403


      100.0%


      $

      59,766


      100.0%

          Allowances and Rebates


      376


      0.7%



      5


      0.0%

      Net Sales


      57,027


      99.3%



      59,761


      100.0%











          Other Revenues


      1,190


      2.1%



      (480)


      -0.8%











      Net Revenues


      58,217


      101.4%



      59,281


      99.2%











          Cost of Goods Sold


      40,284


      70.2%



      39,598


      66.3%











      Gross Profit


      17,933


      31.2%



      19,683


      32.9%











      Operating Expenses










          Selling, General and Administrative Expenses


      8,184


      14.3%



      8,546


      14.3%

          Research and Development Expenses


      2,841


      4.9%



      2,161


      3.6%

      Total Operating Expenses


      11,025


      19.2%



      10,707


      17.9%











      Operating Profit


      6,908


      12.0%



      8,976


      15.0%











      Other Expenses/(Income):










          Interest Expense, net


      1,171


      2.0%



      1,142


      1.9%

          Other Expense/(Income), net


      14


      0.0%



      (41)


      -0.1%











      Income Before Income Taxes


      5,723


      10.0%



      7,875


      13.2%











          Provision for Income Taxes


      2,057


      3.6%



      2,416


      4.1%











      Income from Continuing Operations

      $

      3,666


      6.4%


      $

      5,459


      9.1%











      Income from Discontinued Operations


      1,105


      1.9%



      -


      0.0%











      Net Income

      $

      4,771


      8.3%


      $

      5,459


      9.1%











      Basic Earnings per Share of Common Stock:










        Income from Continuing Operations

      $

      0.12




      $

      0.19



        Income from Discontinued Operations

      $

      0.04




      $

      -



       Net Income

      $

      0.16




      $

      0.19













      Diluted Earnings per Share of Common Stock:










        Income from Continuing Operations

      $

      0.12




      $

      0.19



        Income from Discontinued Operations

      $

      0.04




      $

      -



       Net Income

      $

      0.16




      $

      0.19













      Weighted Average Shares Outstanding










          Basic


      29,333





      29,222



          Diluted


      29,404





      29,247






      CAMBREX CORPORATION

      Statements of Profit and Loss

      For the Six Months Ended June 30, 2010 and 2009

      (in thousands)













      2010


      2009





      % of





      % of



      Amount


      Sales



      Amount


      Sales











      Gross Sales

      $

      113,558


      100.0%


      $

      119,766


      100.0%

          Allowances and Rebates


      712


      0.6%



      338


      0.3%

      Net Sales


      112,846


      99.4%



      119,428


      99.7%











          Other Revenues


      1,464


      1.3%



      885


      0.8%











      Net Revenues


      114,310


      100.7%



      120,313


      100.5%











          Cost of Goods Sold


      81,884


      72.1%



      81,497


      68.1%











      Gross Profit


      32,426


      28.6%



      38,816


      32.4%











      Operating Expenses










          Selling, General and Administrative Expenses


      16,980


      15.0%



      17,594


      14.6%

          Research and Development Expenses


      4,826


      4.2%



      3,898


      3.3%

      Total Operating Expenses


      21,806


      19.2%



      21,492


      17.9%











      Operating Profit


      10,620


      9.4%



      17,324


      14.5%











      Other Expenses/(Income):










          Interest Expense, net


      2,369


      2.1%



      2,299


      2.0%

          Other Expense/(Income), net


      17


      0.0%



      (108)


      -0.1%











      Income Before Income Taxes


      8,234


      7.3%



      15,133


      12.6%











          Provision for Income Taxes


      2,885


      2.6%



      4,936


      4.1%











      Income from Continuing Operations

      $

      5,349


      4.7%


      $

      10,197


      8.5%











      Income from Discontinued Operations


      1,105


      1.0%



      -


      0.0%











      Net Income

      $

      6,454


      5.7%


      $

      10,197


      8.5%











      Basic Earnings per Share of Common Stock:










        Income from Continuing Operations

      $

      0.18




      $

      0.35



        Income from Discontinued Operations

      $

      0.04




      $

      -



       Net Income

      $

      0.22




      $

      0.35













      Diluted Earnings per Share of Common Stock:










        Income from Continuing Operations

      $

      0.18




      $

      0.35



        Income from Discontinued Operations

      $

      0.04




      $

      -



       Net Income

      $

      0.22




      $

      0.35













      Weighted Average Shares Outstanding










          Basic


      29,324





      29,211



          Diluted


      29,402





      29,227






      CAMBREX CORPORATION

      Reconciliation of EBITDA

      For the Quarters and Six Months Ended June 30, 2010 and 2009

      (in thousands)









      Second Quarter 2010



      Second Quarter 2009








      Operating Profit

      $

      6,908



      $

      8,976








      Depreciation and Amortization


      5,226




      4,729








      EBITDA

      $

      12,134



      $

      13,705



















































      Six Months 2010



      Six Months 2009








      Operating Profit

      $

      10,620



      $

      17,324








      Depreciation and Amortization


      10,610




      9,415








      EBITDA

      $

      21,230



      $

      26,739



      CAMBREX CORPORATION

      Consolidated Balance Sheets

      As of June 30, 2010 and December 31, 2009

      (in thousands)















      June 30,



      December 31,

      Assets


      2010



      2009







      Cash and Cash Equivalents

      $

      23,086


      $

      52,365

      Trade Receivables, net


      32,526



      32,025

      Inventories, net


      57,330



      58,369

      Prepaid Expenses and Other Current Assets


      8,146



      6,654

       Total Current Assets


      121,088



      149,413







      Property, Plant and Equipment, net


      140,808



      161,149

      Goodwill and Intangibles, net


      38,216



      36,360

      Other Non-Current Assets


      3,901



      4,593







       Total Assets

      $

      304,013


      $

      351,515







      Liabilities and Stockholders' Equity












      Accounts Payable

      $

      15,669


      $

      17,038

      Accrued Expenses and Other Current Liabilities


      34,137



      38,013

       Total Current Liabilities


      49,806



      55,051







      Long-term Debt


      100,000



      120,800

      Deferred Income Taxes


      15,460



      17,305

      Accrued Pension and Postretirement Benefits


      38,940



      40,963

      Other Non-Current Liabilities


      13,021



      14,126







       Total Liabilities

      $

      217,227


      $

      248,245







       Stockholders’ Equity

      $

      86,786


      $

      103,270







       Total Liabilities and Stockholders’ Equity

      $

      304,013


      $

      351,515




      SOURCE Cambrex Corporation

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.